托珠单抗单药与联合甲氨蝶呤预防类风湿关节炎影像学进展的疗效比较:多项临床试验个体患者数据分析
该研究基于820例早期或已确立类风湿关节炎患者的个体数据,比较托珠单抗单药与托珠单抗联合甲氨蝶呤对2年影像学进展的预防效果。总体联合治疗更有效,但在早期RA基线关节损伤较多或DAS28较低者、以及已确立RA病程较长者中,单药疗效可能接近联合治疗。
要点
- 总体托珠单抗联合甲氨蝶呤比单药更有效预防影像学进展。
- 早期RA基线关节损伤多或DAS28低者,联合优势消失。
- 已确立RA基线病程较长者,联合优势亦消失。
核心结论
- 托珠单抗联合甲氨蝶呤比单药更有效预防影像学进展,但特定亚组中单药疗效可能接近联合治疗。
研究设计与样本
- 基于多项随机试验的个体患者数据,采用混合效应模型分析820例早期或已确立类风湿关节炎患者。
主要发现
- 总体联合治疗在预防总Sharp/van der Heijde评分进展上优于单药。
- 早期RA基线关节损伤较多者联合与单药相对风险分别为1.02与0.91,联合优势消失。
- 早期RA基线DAS28较低者联合与单药相对风险分别为1.04与0.92,联合优势消失。
- 已确立RA基线病程较长者联合与单药相对风险分别为1.04与0.83,联合优势消失。
- 骨侵蚀评分结果与上述一致,关节间隙狭窄评分结果较不明确。
关键数值与推荐
- 影像学进展定义为2年后总SHS、骨侵蚀评分和关节间隙狭窄评分无进展。
- 效应修饰因素包括基线关节损伤、病程和DAS28。
临床怎么用
- 早期RA基线关节损伤较多或DAS28较低、以及已确立RA病程较长者,可考虑托珠单抗单药治疗。
局限性
- 关节间隙狭窄评分结果较不明确。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To compare the effects of preventing radiographic progression (in its 3 components) of tocilizumab (TCZ) monotherapy with those of TCZ and methotrexate (MTX) in combination therapy (TCZ + MTX), and to evaluate possible effect modifiers in this model. METHODS: Randomized trials that compared TCZ monotherapy to TCZ + MTX combination therapy for differences in radiographic progression were analyzed on an individual patient data level using mixed-effects models, and data were collected from 820 subjects with either early rheumatoid arthritis (RA) or established RA. Outcomes were classified as the absence of radiographic progression after 2 years (i.e., preventing radiographic progression) as measured by total Sharp/van der Heijde score (SHS), erosion score, and joint space narrowing (JSN) score. Effect modification by baseline joint damage, disease duration, and Disease Activity Score in 28 joints (DAS28) was studied. RESULTS: Overall, TCZ + MTX combination therapy was more effective in preventing radiographic progression compared to TCZ monotherapy, which was measured by total SHS score. However, in patients with early RA who had more joint damage compared to those with less joint damage at baseline (relative risk [RR] 1.02 versus RR 0.91, respectively) or in patients with a lower DAS28 score compared to those with a higher DAS28 score (RR 1.04 versus RR 0.92, respectively) at baseline, this advantage disappeared. In patients with established RA, the advantage of TCZ + MTX versus TCZ alone in the prevention of radiographic progression disappeared with a longer disease duration at baseline (RR 1.04 versus 0.83). Results of erosion scores as an outcome were in line with these findings, though findings for JSN scores were less clear. CONCLUSION: Combination therapy with TCZ + MTX is more effective in preventing radiographic progression compared to TCZ monotherapy, but the effectiveness of TCZ monotherapy may approximate the effectiveness of TCZ + MTX in patients with early RA who have more joint damage and/or a lower DAS28 at baseline and in patients with established RA who have longer disease duration.
引用
- Verhoeven MMA, Tekstra J, Jacobs JWG, et al. Efficacy of Tocilizumab Monotherapy Versus Tocilizumab and Methotrexate Combination Therapy in the Prevention of Radiographic Progression in Rheumatoid Arthritis: An Analysis Using Individual Patient Data From Multiple Clinical Trials. Arthritis Care Res (Hoboken). 2022. PMID: 33253497. doi:10.1002/acr.24524
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。